1.An Interpretation of the Modern version of Hippocratic Oath
Xianglin CHI ; Zhaorong GUO ; Li ZHOU ; Honghao MAN ; Xijuan WU ; Chunyu DONG
Chinese Medical Ethics 1995;0(04):-
With the rapid development of medicine,medical ethics and medical philosophy have also made a far step forward.Under the new historical conditions,they are endowed with a new scientific connotation,which is elaborated in the modern version of Hippocratic Oath.
2.Advances of molecular mechanisms of oxidative stress in obstructive sleep apnea syndrome and stroke
Honghao MAN ; Shuqiang YAO ; Yongpeng YU ; Yuhua BI ; Chunyu DONG ; Xiaohong QIAO ; Weiping JU
Chinese Journal of Primary Medicine and Pharmacy 2017;24(3):462-465
Obstructive sleep apnea (OSA)is a high incidence of potentially dangerous disease,characterized by intermittent hypoxia or hypercapnia.It is an independent risk factor for ischemic stroke.Currently a number of studies have confirmed OSA closely associated with oxidative stress.In this paper,the complex mechanisms of oxidative stress in the OSA and the occurrence of stroke will be reviewed,such as promoting atherosclerosis,damaging the mitochondria,ischemia -reperfusion injury,ischemic preconditioning.To investigate the relationship between OSA,oxidative stress and stroke from molecular mechanisms.
3.Relationship Between Lysophosphatidic Acid Levels in Cerebrospinal Fluid and Cerebral Vasospasm After Subarachnoid Hemorrhage
Zhancai YU ; Zhenguang LI ; Qizhuan WU ; Haiming CONG ; Honghao MAN ; Dongxiao JIANG ; Xia LI ; Xinhu SUN ; Xianglin CHI ; Chaoshu TANG
International Journal of Cerebrovascular Diseases 2008;16(2):117-120
Objective: To observe the characteristics of dynamic changes of lysophosphatidic acid (LPA) levels in cerebrospinal fluid (CSF) in patients with subarachnoid hemorrhage (SAH) and its relationship with cerebral vasospasm (CVS) and to explore the pathogenesis of CVS. Methods: Sixty-seven patients with SAH diagnozed by clinical and accessory examinations were selected. The LPA levels in CSF were measured at 24 hours, day 7,14, and 28 respectively after the onset of symptoms,and they were compared with a control group. The correlation between LPA levels and CVS on the time course was also observed at the same time. Results: Of the 67 patients with SAH, a total of 29 patients (43.3%) occurred CVS, the average time of occurrence was 6. 6 days. There was no significant difference between the LPA levels in CSF in patients with SAH and the control group at 24 hours after the onset of symptoms; they were significantly higher than the control group at day 7 (P <0. 001); they were significantly higher than the control group at day 14 (P < 0. 001), but they were significantly lower than those at day 7 (P < 0. 01); they decreased to baseline at day 28, and there was significant difference compared with the control group. There was no significant difference between the LPA levels in the CVS group and those in the non-CVS group at 24 hours, they were significantly higher than those in the non-CVS group at day 7 (P <0. 001), they were still significantly higher than those in the non-CVS group at day 14 (P <0. 01); and there was no significant difference between the 2 groups at day 28. Conclusions: The LPA levels in CSF in patients with SAH increased significantly from day 7 to day 14 after the onset of symptoms, and they had obvious association with CVS on the time course. The detection of the LPA levels in CSF may have important significance in predicting the occurrence of CVS.
4.Rete middle cerebral artery
Fuhao ZHENG ; Zhenming ZHAO ; Honghao MAN
International Journal of Cerebrovascular Diseases 2020;28(8):625-628
Rete middle cerebral artery is an abnormal process of embryonic development, which results in the normal middle cerebral artery trunk being replaced by plexiform vascular network. The main clinical manifestations are intracranial hemorrhage or ischemic cerebrovascular events. Clinicians generally do not know enough about it. This article reviews the generative mechanism, clinical manifestations, differential diagnosis and treatment of the rete middle cerebral artery.